Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GPR35 | Q9HC97 | 2/20 | 0.37 |
| ▸ | NOTUM | Q6P988 | 5/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.31 |
| ▸ | LMNA | P02545 | 1/20 | 0.31 |
| ▸ | PIP4K2C | Q8TBX8 | 1/20 | 0.31 |
| ▸ | GPR119 | Q8TDV5 | 1/20 | 0.31 |
| ▸ | NPC1 | O15118 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.30 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL441091 | 0.77 | GPR35 (0.41) | GPR35NOTUMPIP4K2CGPR119NPC1 | |
| SCHEMBL441195 | 0.76 | AXL (0.37) | GPR35NOTUMALDH1A1PIP4K2CGPR119 | |
| SCHEMBL439335 | 0.76 | NOTUM (0.47) | NOTUMALDH1A1MAPT | |
| SCHEMBL438091 | 0.75 | GPR35 (0.37) | GPR35ALDH1A1PIP4K2CGPR119NPC1 | |
| SCHEMBL23519908 | 0.75 | NPC1 (0.47) | NOTUMALDH1A1LMNANPC1PKM | |
| SCHEMBL2235502 | 0.75 | ALDH1A1 (0.35) | NOTUMALDH1A1LMNAPIP4K2CNPC1 | |
| SCHEMBL21823142 | 0.74 | ALDH1A1 (0.36) | NOTUMALDH1A1LMNAMAPT | |
| SCHEMBL12432761 | 0.73 | TP53 (0.36) | ALDH1A1LMNANPC1PKMMAPT | |
| SCHEMBL21823085 | 0.73 | MAPK1 (0.42) | GPR35PIP4K2CGPR119NPC1PKM | |
| SCHEMBL10807053 | 0.71 | HIF1A (0.46) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | INVENTIVA (FR) | 2024-06-04 | — | — | US | disclosed |
| EP-3860990-B1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | INVENTIVA (FR) | 2022-09-14 | — | — | EP | disclosed |
| US-20210323982-A1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | INVENTIVA (FR) | 2021-10-21 | — | — | US | disclosed |
| EP-3860990-A1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | Inventiva (FR) | 2021-08-11 | — | — | EP | disclosed |
| WO-2020070181-A1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | INVENTIVA (FR) | 2020-04-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323982-A1 | INHIBITORS OF THE YAP/TAZ-TEAD INTERACTION AND THEIR USE IN THE TREATMENT OF CANCER | YAP1, TEAD2, YES1 | GPR35 4126/4885NOTUM 4397/4885ALDH1A1 2232/4885 |
| US-11999758-B2 | Inhibitors of the YAP/TAZ-TEAD interaction and their use in the treatment of cancer | YAP1, TEAD2, YES1 | GPR35 4126/4885NOTUM 4397/4885ALDH1A1 2232/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.